Skip to content
ALLO·Nasdaq·US

Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic CAR-T cell therapies for cancer and autoimmune diseases. The company is advancing an off-the-shelf cell therapy pipeline rather than commercialized products, and it currently has minimal revenue.

Thematic Position

ALLO

Relationship Groups

Suppliers2
Licensing2
Competitors9

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

18 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

data localizationcross-border data transfer restriction
EEA and UK restrict cross-border transfer of personal data to the United States
SEC 10-KMar 12, 2026

The full regulatory passage is part of the Pro plan.

12 more · Regulatory and geopolitical insights are part of the Pro plan.